3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
6
pembrolizumab
5
fludarabine
4
fludarabine phosphate
2
amatuximab
2
SS1(dsFv)PE38
2
tocilizumab
1
sotorasib
1
sargramostim
1
enzalutamide
1
entinostat
1
defactinib
1
bemcentinib
1
aldesleukin
1
alanosine
1
Tablets
1
Sorafenib
1
Sirolimus
1
Quality of Life
1
Polymerase Chain Reaction
1
Pentostatin
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Ipilimumab
1
Interleukin-12 Subunit p35
1
Interferon-gamma
1
Interferon-alpha
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Blood Component Removal
×
Other solid neoplasm
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled